ICI therapy works by blocking the interaction between programmed death ligand 1 (PD-L1) on tumor cells and programmed cell death protein 1 (PD-1) on T cells, thereby enabling T cells to effectively eliminate tumor cells. The gene discussed is PDCD1; the disease is neoplasm.